Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline

被引:22
|
作者
Sachs, Gary S.
Gaulin, Bruce D.
Gutierrez-Esteinou, Rolando
McQuade, Robert D.
Pikalov, Andrei, III
Pultz, Joseph A.
Sanchez, Raymond
Marcus, Ronald N.
Crandall, David I.
机构
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Bristol Myers Squibb Co, Plainsboro, NJ USA
[3] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[4] Otsuka Amer Pharmaceut Inc, Princeton, NJ USA
[5] Otsuka Amer Pharmaceut Inc, Rockville, MD USA
[6] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
关键词
D O I
10.4088/JCP.v68n0908
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: To examine the antimanic efficacy of the relatively nonsedating antipsychotic aripiprazole in patients with bipolar I disorder and high or low baseline levels of agitation. Method: Data were pooled for this post hoc analysis from two 3-week, placebo-controlled trials of aripiprazole in acute mania (DSM-IV). Patients randomly assigned to aripiprazole 30 mg/day (N = 259) or placebo (N = 254) were Classified as having either high (Positive and Negative Syndrome Scale [PANSS] Excited Component [PEC] score of >= 14 and a score of >= 4 on at least one PEC item) or low (PEC < 14) levels of agitation at baseline. Efficacy measures were changes in Young Mania Rating Scale (YMRS) scores, Clinical Global Impressions-Bipolar (CGI-BP) scores, and PEC scores. Efficacy and agitation measurements were assessed by analysis of covariance. Results: From the first week of therapy onward, aripiprazole-treated subjects had significantly greater reduction from baseline in YMRS total scores than placebo-treated subjects in both the high- and low-agitation groups (p <.05 for both groups) and significantly improved CGI-BP scores vs. placebo at end point (p <.05 for both). In highly agitated patients receiving aripiprazole, PEC scores were significantly decreased versus placebo at end point (p <.05). In patients with low agitation receiving aripiprazole, no increases in PE scores were seen, and a significant reduction in agitation symptoms was apparent after adjustment for baseline PEC scores. Conclusions: Aripiprazole was superior to placebo in reducing the severity of both mania and agitation in highly agitated patients with bipolar I disorder and showed significant antimanic activity in patients with low levels of agitation without increasing agitation. These findings suggest that aripiprazole's antimanic effect is specific and not limited to control of agitation through sedation.
引用
收藏
页码:1377 / 1383
页数:7
相关论文
共 50 条
  • [31] Long-term tolerability and safety of aripiprazole in pediatric patients with schizophrenia or bipolar I disorder
    Nyilas, M.
    Correll, C.
    Werner, C.
    Forbes, R.
    Johnson, B.
    Aurang, C.
    Jin, N.
    Owen, R.
    Iwamoto, T.
    Carson, W.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 133 - 134
  • [32] The Antimanic Effect of Endoxifen in Patients with Bipolar Disorder with Renal Comorbidities: Case Series
    Kuraria, Astut
    Vishwanath, Rashmi
    Nagaraj, Anil Kumar M.
    Soman, Savitha
    Kamath, Avinash
    INDIAN JOURNAL OF PSYCHOLOGICAL MEDICINE, 2024,
  • [33] Aripiprazole treatment for acute mania in patients with bipolar I disorder: A placebo-controlled study
    Grunze, H
    Carson, W
    Sachs, G
    Sanchez, R
    Marcus, R
    Kujawa, M
    Archibald, D
    Iwamoto, T
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S264 - S264
  • [35] An Open Prospective Trial of Aripiprazole in Children and Adolescents with Bipolar I Disorder
    Danielyan, Arman
    Cannon, Michael
    Kowatch, Robert A.
    BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 233S - 233S
  • [36] Response to mood stabilizers in older patients with bipolar I disorder
    Calabrese, J
    Sajatovic, M
    Laszlo, G
    White, R
    Evoniuk, G
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S153 - S154
  • [37] Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the Prophylaxis of Bipolar Disorder Type I with Manic Predominance
    Mauri, Massimo Carlo
    Reggiori, Alessandra
    Minutillo, Alessandro
    Franco, Gemma
    Di Pace, Chiara
    Paletta, Silvia
    Cattaneo, Dario
    PHARMACOPSYCHIATRY, 2020, 53 (05) : 209 - 219
  • [38] Long-term aripiprazole effectiveness in bipolar disorder patients decreases with pharmacotherapeutic complexity and degree of baseline mood disturbance
    Ittasakul, Pichai
    Miller, Shefali
    Wang, Po W.
    Hill, Shelley J.
    Childers, Meredith E.
    Ketter, Terence A.
    ASIAN BIOMEDICINE, 2013, 7 (04) : 537 - 544
  • [39] Sustained remission in bipolar I disorder: An post-hoc analysis of an aripiprazole bipolar study
    Masand, Prakash
    Eudicone, James
    Pikalov, Andrei
    McQuade, Robert
    Vester-Blokland, Estelle
    Carlson, Berit
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S227 - S227
  • [40] Sublingual Dexmedetomidine for the Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
    Smith, Colin M.
    Santalucia, Morgan
    Bunn, Hannah
    Muzyk, Andrew
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2023, 21 (02) : 215 - 221